Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
a study on Bladder Cancer Cervical Cancer Cholangiocarcinoma Hematopoietic and Lymphoid Cell Neoplasm Hepatocellular Cancer Liver Cancer Adrenal Gland Neoplasm Brain Tumor Pleural Neoplasm Skin Cancer/Melanoma Solid Neoplasm Testicular Cancer Thymus Neoplasm Neuroendocrine Neoplasm Thyroid Cancer Transitional Cell Carcinoma Cancer of Unknown Primary Site Cancer, General Carcinoma Neoplasms Brain Cancer Urinary Bladder Tumor Neuroendocrine Tumor
Bladder Carcinoma, Cervical Carcinoma, Cholangiocarcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Hepatocellular Carcinoma, Malignant Adrenal Gland Neoplasm, Malignant Brain Neoplasm, Malignant Pleural Neoplasm, Malignant Skin Neoplasm, Malignant Solid Neoplasm, Malignant Testicular Neoplasm, Malignant Thymus Neoplasm, Neuroendocrine Neoplasm, Thyroid Gland Carcinoma, Urothelial Carcinoma, Cancer of Unknown Primary Site, Carcinoma, Neoplasms, Brain Neoplasms, Urinary Bladder Neoplasms, Neuroendocrine Tumors, Thyroid Neoplasms, Skin Neoplasms, Testicular Neoplasms, Pleural Neoplasms, Unknown Primary Neoplasms, Thymus Neoplasms, Adrenal Gland Neoplasms, Fluorodeoxyglucose F18, FAPI-46, Computed Tomography, Gallium Ga 68 FAPi-46, Positron Emission Tomography, 18F-FDG, Basic science (68GA-FAPI-46 PET/CT)
Lead Scientist at UCLA
- Jeremie Calais
Nuclear medicine physician specialized in cancer imaging and theranostics. Associate Professor, Department of Molecular and Medical Pharmacology at UCLA Director, Theranostics Program, Ahmanson Translational Theranostics Division at UCLA Faculty Member of the Jonsson Comprehensive Cancer Center at UCLA. Faculty Member of the Institute of Urologic Oncology at UCLA.